Oppenheimer Assigned a Buy Rating to The Ensign GroupBy Jason Carr
In a report released yesterday, Michael Wiederhorn from Oppenheimer assigned a Buy rating to The Ensign Group (NASDAQ: ENSG), with a price target of $29. The company’s shares closed yesterday at $18.36, close to its 52-week low of $17.60.
According to TipRanks.com, Wiederhorn is a top 25 analyst with an average return of 13.8% and a 61.7% success rate. Wiederhorn covers the Healthcare sector, focusing on stocks such as Addus Homecare Corp., Envision Healthcare, and Genesis Healthcare.
The Ensign Group has an analyst consensus of Strong Buy, with a price target consensus of $29.
The company has a one year high of $24.85 and a one year low of $17.60. Currently, The Ensign Group has an average volume of 289.7K.
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ENSG in relation to earlier this year. Most recently, in August 2016, Chad Keetch, the EVP of ENSG bought 5,000 shares for a total of $35,493.
The Ensign Group, Inc. engages in the provision of healthcare services across the post-acute care continuum, as well as urgent care centers and mobile ancillary businesses. It operates through the Transitional, Skilled, and Assisted Living Services and Home Health and Hospice Services segment. The Transitional, Skilled, and Assisted Living Services segment includes the operation of skilled nursing facilities, assisted and independent living facilities. The Home Health and Hospice Services segment includes home health, home care, and hospice businesses. The company was founded by Roy E. Christensen and Christopher R. Christensen in 1999 and is headquartered in Mission Viejo, CA.